Arcutis Biotherapeutics, Inc. (ARQT)
| Market Cap | 1.75B |
| Revenue (ttm) | 138.71M |
| Net Income (ttm) | -195.54M |
| Shares Out | 117.04M |
| EPS (ttm) | -1.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,874,262 |
| Open | 14.25 |
| Previous Close | 14.11 |
| Day's Range | 14.18 - 15.77 |
| 52-Week Range | 2.60 - 15.77 |
| Beta | 1.32 |
| Analysts | Strong Buy |
| Price Target | 15.50 (+3.4%) |
| Earnings Date | Nov 6, 2024 |
About ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topic... [Read more]
Financial Performance
In 2023, Arcutis Biotherapeutics's revenue was $59.61 million, an increase of 1517.09% compared to the previous year's $3.69 million. Losses were -$262.14 million, -15.83% less than in 2022.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ARQT stock is "Strong Buy." The 12-month stock price forecast is $15.5, which is an increase of 3.40% from the latest price.
News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WESTLAKE VILLAGE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Following the successful product launch of Zoryve, Arcutis Biotherapeutics has returned an impressive +200% year-to-date. Recent Q3 earnings impressed, with a blistering 452% year-over-year and 45% qu...
Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Investor Relations Frank Wat...
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical foam 0.3%, and $2.5M for ZORYVE cream 0.15%; sales growth...
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference
WESTLAKE VILLAGE, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in i...
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in over two decades1 Second approval of ZORYVE outside of the United Stat...
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types
ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of race, ethnicity, and Fitzpatrick skin type ZORYVE was safe ...
FDA Accepts Arcutis' Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) target action date of May 22, 2025 Almost half of the 9 million individuals in the United States with plaque ps...
Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
Arcutis Biotherapeutics, Inc. is a biotech company based in California that markets two dermatological products, ZORYVE cream and foam, containing roflumilast, a PDE4 inhibitor. Despite initial strugg...
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
WESTLAKE VILLAGE, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Arcutis Biotherapeutics, Inc. (ARQT) Q2 2024 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Latha Vairavan - VP, Finance and Head of IR Frank Watanabe - President & C...
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
WESTLAKE VILLAGE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), please note that in the section o...
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
Second quarter net product revenues for ZORYVE® franchise of $30.9M, with $17.3M for ZORYVE (roflumilast) cream 0.3%, and $13.6M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 547% vs. Q...
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
Over 200-person sales force to promote ZORYVE (roflumilast) in primary care and pediatric practices Provides access to a large portion of the 7.4 million individuals treated for plaque psoriasis, sebo...
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
Once-daily, effective, safe, and well-tolerated ZORYVE cream now commercially available Provides rapid clearance of atopic dermatitis signs and symptoms and significant reduction in itch, and can be u...
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
WESTLAKE VILLAGE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in i...
FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
ZORYVE cream provides rapid relief, with efficacy, safety, and tolerability demonstrated up to 56 weeks of treatment ZORYVE cream rapidly and significantly reduces itch, the most bothersome symptom of...
Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
Investigational roflumilast cream 0.15% showed continued improvements in the signs and symptoms of AD, including itch, through 56 weeks of treatment 66.2% of participants treated with once-daily roflu...
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2024 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Latha Vairavan - Vice President, Finance and Head of Investor Relations Frank...
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
First quarter net product revenues for ZORYVE® franchise of $21.6M, with $15M for ZORYVE (roflumilast) cream 0.3%, and $6.5M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 675% vs. Q1 '2...
Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
Eight of nine experts expressed feeling “extremely confident” about prescribing ZORYVE foam to patients of diverse skin and hair types, including individuals with previous hair treatments, based on re...
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
WESTLAKE VILLAGE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...
Arcutis Appoints David Topper as Chief Financial Officer
WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatolog...
